TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-16
SponsorHamilton Health Sciences Corporation
About this trial
Tree nut immunotherapy Route Assessment and DEvelopment (TRADE) is a randomized controlled trial that evaluates the efficacy and safety of sublingual immunotherapy and lower, more tolerable, doses of oral immunotherapy than currently in use.
Eligibility criteria
Qualifiers
Allergic to tree nut with baseline threshold of 444 mg protein or less and provides consent, and where applicable, assent.
Disqualifiers
History of anaphylaxis to tree nut severe enough to cause shock, syncope, or intubation
Eosinophilic or other inflammatory gastrointestinal disease within the past 2 years
Severe (GINA severity class 5) or uncontrolled asthma including exacerbation within past 6 months
Use of biologics, other food immunotherapy or experimental treatment in past 6 months.
Trial design
Treatments tested in this trial
- Food
Treatment groups
60 Participants
are divided into 3 treatment groupsSponsors and collaborators
Hamilton Health Sciences Corporation
Lead sponsor
AAAAI Foundation
Collaborator
Source ClinicalTrials.gov